Home › Cancro al seno › New York › Rochester
Studi clinici su Cancro al seno a Rochester, NY
15 studi su Cancro al seno cercano partecipanti presso sedi a Rochester e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
In reclutamentoFase 3
- Rochester General Hospital Lipson Cancer Institute, Rochester
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
In reclutamentoFase 2
- University of Rochester Medical Center, Rochester
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
In reclutamento
- University of Rochester (URMC), Rochester
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
In reclutamentoFase 2
- Wilmot Cancer Institute, Rochester
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
In reclutamentoFase 3
- University of Rochester Medical, Rochester
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
In reclutamentoFase 1
- Wilmot Cancer Institute, Rochester
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
In reclutamentoFase 2
- University of Rochester Medical Center, Rochester
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
In reclutamentoFase 3
- Pluta Cancer Center, Rochester
- University of Rochester, Rochester
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
In reclutamentoFase 1
- University of Rochester - Wilmot Cancer Institute, Rochester
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
In reclutamentoFase 2
- University of Rochester Wilmot Cancer Institute, Rochester
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
In reclutamentoFase 3
- Wilmot Cancer Institute Radiation Oncology at Greece, Rochester
- Highland Hospital, Rochester
- Pluta Cancer Center, Rochester
- e altri 3
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
In reclutamento
- University of Rochester, Rochester
Access to Genetic Testing in Underserved Patients With Cancer
In reclutamentoVolontari sani benvenuti
- University of Rochester, Rochester
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
In reclutamentoFase 2
- University of Rochester, Rochester
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
In reclutamentoStudio osservazionale
- University of Rochester - Pluta Cancer Center, Rochester
Studi su Cancro al seno in altre città
- New York City, NY137 studi
- Houston, TX127 studi
- Boston, MA113 studi
- Nashville, TN80 studi
- Los Angeles, CA72 studi
- Edison, NJ67 studi
- St. Louis, MO65 studi
- Durham, NC64 studi
- Queens, NY63 studi
- Chicago, IL59 studi
- Philadelphia, PA57 studi
- Dallas, TX56 studi
Altri studi a Rochester
- Leucemia mieloide acuta16 studi
- Cancro ai polmoni15 studi
- Cancro (tutti i tipi)14 studi
- Cancro del polmone non a piccole cellule13 studi
- Obesità13 studi
- Sovrappeso12 studi
- Cancro alla prostata10 studi
- Cancro metastatico8 studi
- Mieloma multiplo8 studi
- Cancro della vescica7 studi
- Cancro pancreatico7 studi
- Distrofia miotonica7 studi
Fonte: ClinicalTrials.gov, dati recuperati il 7 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.